Ann: MXC Operational and Strategy Update, page-29

I am not sure whether your comments are an underhanded shot at me. What l take from your summary is MXC is shackled by the number of shares on issue. The amount of dilution is a concern for many, me included. The elephant in the room is multi factorial, so l do not think a simplified response like number of share on issue is necassarily the end of the issue. The popularity of medical marijuana stocks, the ability of individual companies to commercialise sales, the ability of companies to value add, the ability of companies to research back their therapeutic claims. To simplify net intrinsic value based on X amount of shares is niaeve. No one has commented on PE ratios which we all know magnifies a companies share price based on industry averages and an individual companies gross annual sales.

As l said before at least 3 times, if a conservative PE ratio of 10 is adopted for the medical marijuana industry sector, then fruition of the VC deal should theoretically justify an MXC SP of 40 cents. Even with the current amount of shares on issue. Given that it is very early days and the likelihood of many more commercial contracts, it seems entirely conceivable MXC could generate sales of more than 100 million dollars. On the 10-1 PE model, a $1.00 SP is possible.
So the limiting factor is really the commercial viability of this company rather than the amount of shares on issue. When we analyze the impending market value/demand projections for MM products and beauty products - an astute person might think the number of shares on issue right now can be well accommodated in the medium term. In fact my personal feelings are it is no concern provided no further dilution is forced on us.